Federation of State Medical Boards (FSMB) + state medical practice acts (50 states) · United States
FSMB Aesthetic Medicine Guidelines + State Medical Practice Acts — Med Spa Advertising
Med spa ads for medical aesthetic procedures must not claim no risk, guaranteed or permanent results, or imply prescription drugs need no evaluation, and must be accurate about who performs procedures.
What is FSMB Aesthetic Medicine Guidelines + State Medical Practice Acts — Med Spa Advertising?
Med spa ads for medical aesthetic procedures must not claim no risk, guaranteed or permanent results, or imply prescription drugs need no evaluation, and must be accurate about who performs procedures. Med spa and aesthetic clinic advertising for injectables, lasers, body contouring, IV therapy and weight-loss injections.
general_audience, general_adults_18plus, customers · Med Spa · healthcare
Where does this rule apply?
United States
Which marketing channels are covered?
all_channels
When does this rule take effect?
2026-11-06
What does this rule require?
Med spa ads for medical aesthetic procedures must not claim no risk, guaranteed or permanent results, or imply prescription drugs need no evaluation, and must be accurate about who performs procedures.
How can marketing teams comply?
Med spa and aesthetic clinic advertising for injectables, lasers, body contouring, IV therapy and weight-loss injections.
What is FSMB Aesthetic Medicine Guidelines + State Medical Practice Acts — Med Spa Advertising?
Med spa ads for medical aesthetic procedures must not claim no risk, guaranteed or permanent results, or imply prescription drugs need no evaluation, and must be accurate about who performs procedures.
Who does this rule apply to?
general_audience, general_adults_18plus, customers · Med Spa · healthcare
Program marketing at Title IV institutions must not misrepresent graduate earnings or outcomes, and programs warned under the Gainful Employment rule must give the required student warning; rule status is in flux after the 2025 budget law.
REACH governs chemicals in EU products; in marketing, chemical free-from and REACH-status claims must be accurate and not misleading, and REACH compliance may not be presented as a distinctive benefit.
The FTC Act bars deceptive advertising: objective claims need a reasonable basis before they run, and qualifications and material terms must be clear and conspicuous so the net impression is not misleading.
Unqualified 'Made in USA' and similar claims, including hashtags and seals, require final assembly, all significant processing and all or virtually all components in the U.S.; otherwise claims must be clearly qualified.
FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit.
Data in promotion that are not in the labeling, including real-world evidence, must be consistent with the approved conditions of use and be presented with the study design, limitations and context needed to avoid misleading the reader.
Request a free compliance scan of your homepage and book a time with Warrant.